[3] In 2011, the U.S. FDA approved ipilimumab, a monoclonal antibody to CTLA-4, for treatment of metastatic melanoma.
[1] In 2014, the U.S. FDA approved nivolumab, a monoclonal antibody to PD-1, for treatment of advanced melanoma.
Michael W. Fanger, Dr. Paul M. Guyre, and Dr. Edward D. Ball — who partnered with Donald L. Drakeman and Charles Schaller of Essex Chemical Company, through its venture capital arm Essex Vencap.
[citation needed] Drakeman, a Dartmouth graduate, brought the parties together and served as the company's chief executive officer.
[9] Genmab was founded as a European spin-off of American Biotech company Medarex in February 1999.